Latest News

Follow market-moving stories, policy signals, and company developments curated by the editorial desk.

Latest
贏得藥物開發權仲裁 Prime Medicine 股價大漲逾11%

贏得藥物開發權仲裁 Prime Medicine 股價大漲逾11%

Jul 8, 2026

基因編輯公司 Prime Medicine 在與 Beam Therapeutics 的仲裁案中獲勝,確認其對罕見遺傳病藥物 PM647 的開發權利。此消息激勵 Prime Medicine 股價上漲超過11%,而 Beam Therapeutics 股價則下跌。